Intensive short-term chemotherapy regimen induces high remission rate (over 90%) and event-free survival both in children and adult patients with advanced sporadic Burkitt lymphoma/leukemia

American Journal of Hematology

Volumn 87, Issue 1, 2012, Pages 22-25

  Todeschini, Giuseppe ^a   Bonifacio, Massimiliano ^a   Tecchio, Cristina ^a   Balter, Rita ^b   Carli, Giuseppe ^a   Stefani, Piero Maria ^c   Adami, Fausto ^d   Zamò, Alberto ^e   Tos, Angelo Paolo Dei ^c   Marino, Filippo ^f   Gherlinzoni, Filippo ^c   Marradi, Pierluigi ^b   Semenzato, Giampietro ^d   Pizzolo, Giovanni ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b UNIVERSITY HOSPITAL OF VERONA   (Italy)

^c CA FONCELLO HOSPITAL   (Italy)

^d UNIVERSITY OF PADUA MEDICAL SCHOOL   (Italy)

^e UNIVERSITY OF VERONA   (Italy)

^f UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; FOLINIC ACID; FUROSEMIDE; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE; RASBURICASE; RITUXIMAB; VINCRISTINE;

ADOLESCENT; ADULT; AGED; ARTICLE; BACTERIAL PNEUMONIA; BURKITT LYMPHOMA; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER REGRESSION; CANCER RELAPSE; CANCER STAGING; CELL COUNT; CHILD; DRUG MEGADOSE; EVENT FREE SURVIVAL; FEMALE; HEART INFARCTION; HUMAN; LEUKEMIA; MALE; MULTICENTER STUDY; MULTIPLE ORGAN FAILURE; NEUTROPHIL COUNT; ORAL REHYDRATION THERAPY; PHAGOCYTE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SHORT COURSE THERAPY; STEM CELL TRANSPLANTATION; THROMBOCYTE COUNT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; URINE PH;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BURKITT LYMPHOMA; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; REMISSION INDUCTION; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84155167899     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.22189     Document Type: Article

References (17)

1. Burkitt D. A sarcoma involving the jaws in African children. Br J Surg 1958; 46: 218-223.
2. Perkins AS, Friedberg JW. Burkitt lymphoma in adults. Hematology Am Soc Hematol Educ. Program 2008; 341-348.
3. Smeland S, Blystad AK, Kvaloy SO, et al. Treatment of Burkitt's/Burkitt-like lymphoma in adolescents and adults: A 20-year experience from the Norwegian Radium Hospital with the use of three successive regimens. Ann Oncol 2004; 15: 1072-1078.
4. Hoelzer D, Ludwig WD, Thiel E, et al. Improved outcome in adult B-cell acute lymphoblastic leukemia. Blood 1996; 87: 495-508.
5. Magrath I, Adde M, Shad A, et al. Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol 1996; 14: 925-934.
6. Mead GM, Sydes MR, Walewsky J, et al. An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: Results of United Kingdom Lymphoma Group LY06 study. Ann Oncol 2002; 13: 1264-1274.
7. Rizzieri DA, Johnson JL, Niedzwiecki D, et al. Intensive chemotherapy with and without cranial radiation for Burkitt leukemia and lymphoma: Final results of Cancer and Leukemia Group B Study 9251. Cancer 2004; 100: 1438-1448.
8. Di Nicola M, Carlo-Stella C, Mariotti J, et al. High response rate and manageable toxicity with an intensive, short-term chemotherapy programme for Burkitt's lymphoma in adults. Br J Haematol 2004; 126: 815-820.
9. Thomas DA, Cortes J, O'Brien S, et al. Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia. J Clin Oncol 1999; 17: 2461-2470.
10. Thomas DA, Faderl S, O'Brien S, et al. Chemoimmunotherapy with Hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer 2006; 106: 1569-1580.
11. Murphy SB, Bowman WP, Abromowitch M, et al. Results of treatment of advanced-stage Burkitt's lymphoma and B cell (S Ig+) acute lymphoblastic leukemia with high-dose fractionated cyclophosphamide and coordinated high-dose methotrexate and cytarabine. J Clin Oncol 1986; 4: 1732-1739.
12. Todeschini G, Tecchio C, Degani D, et al. Eighty-one percent event-free survival in advanced Burkitt's lymphoma/leukemia: No differences in outcome between pediatric and adult patients treated with the same intensive pediatric protocol. Ann Oncol 1997; 8: S77-S81.
13. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol 1999; 17: 1244-1253.
14. Kujawski LA, Longo WL, Williams EC, et al. A 5-drug regimen maximizing the dose of cyclophosphamide is effective therapy for adult Burkitt or Burkitt-like lymphomas. Cancer Invest 2007; 25: 87-93.
15. van Imhoff GW, van der Holt B, MacKenzie MA, et al. Short intensive sequential therapy followed by autologous stem cell transplantation in adult Burkitt, Burkitt-like and lymphoblastic lymphoma. Leukemia 2005; 19: 945-952.
16. Mead GM, Barrans SL, Qian W, et al. A prospective clinicopathological study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial). Blood 2008; 112: 2248-2260.
17. Friedberg JW, Ciminello L, Kelly J, et al. Outcome of patients > age 40 with Burkitt lymphoma (BL) treated with aggressive chemotherapeutic regimens: Results from the International Burkitt Lymphoma Collaborative Group. Blood (ASH Annual Meeting Abstracts) 2005; 106: Abs#928.